SUBSCRIBERS
Temasek leads US$85m investment round for gene therapy startup
Published Tue, Feb 26, 2019 · 09:50 PM
Singapore
IMMUNE cell gene therapy startup Gracell Biotechnologies has raised US$85 million through a Series B round led by Singapore government investment firm Temasek Holdings.
Also taking part in the financing round were Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
China’s top airlines improve balance sheet in Q1; outlook positive for May Day
Stablecoin issuer Tether invests US$200 million in brain-computer interface company
Yahoo to lay off staff in Singapore as it shifts to content curation
US: Wall St opens higher on megacap strength, Fed verdict awaited
IReit Global occupancy rate grows to 91.5% in Q1
Yen surges against US dollar on suspected intervention